about
Optimal loading dose of warfarin for the initiation of oral anticoagulationRole of beta 2-glycoprotein I and anti-phospholipid antibodies in activation of protein C in vitroD-dimer test for excluding the diagnosis of pulmonary embolismThe management of heparin-induced thrombocytopenia.Have You Been HIT?Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition.Haemolytic uraemic syndrome after bone marrow transplantation: an adverse effect of total body irradiation?Haematological manifestations of systemic lupus erythematosus.Optimal loading dose for the initiation of warfarin: a systematic reviewThe diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization.The prevalence of the cysteine1584 variant of von Willebrand factor is increased in type 1 von Willebrand disease: co-segregation with increased susceptibility to ADAMTS13 proteolysis but not clinical phenotype.Inherited coagulation disorders.The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology.Combined oral contraceptives and the risk of myocardial infarction.Duration of anticoagulation: decision making based on absolute risk.The use of age-dependent D-dimer cut-off values to exclude deep vein thrombosis. Reply to "Using an age-dependent D-dimer cut-off value increases the number of older patients in whom deep vein thrombosis can be safely excluded". Haematologica 2012;9The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.Predicting the future: it's not a SNP.Audit of anticoagulation after embolectomy for acute ischaemia.The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran.Management of muscle haematomas in patients with severe haemophilia in an evidence-poor world.Managing antiplatelet and anticoagulant drugs in patients undergoing elective ophthalmic surgery.Diagnosis and management of heritable thrombophilias.Controversies in venous thromboembolism--2015.The aspirin story - from willow to wonder drug.The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.Fatal thromboembolism in acute promyelocytic leukaemia treated with a combination of all-trans retinoic acid and aprotonin.A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use.Treating alcohol dependence. One glass of wine is usually 1.5 units.Comparison of a point of care device against current laboratory methodology using citrated and EDTA samples for the determination of D-dimers in the exclusion of proximal deep vein thrombosis.Von Willebrand disease, angiodysplasia and atorvastatin.Sagittal sinus thrombosis in a teenager: homocystinuria associated with reversible antithrombin deficiency.Changing patterns of bleeding in patients with severe haemophilia A.Multiple transient ischaemic attacks and a mild thrombotic stroke in a HIV-positive patient with anticardiolipin antibodies.Management of bleeding in patients taking FXa and FIIa inhibitors.The use of rituximab in two children with allo-antibodies towards factor VIII.Idarucizumab for dabigatran overdose in a child.Factor VIII assays in haemophilia a patients treated with ReFacto.A single dose of Low-molecular-weight Heparin (LMWH) invalidates the use of D-dimer as part of a Deep Vein Thrombosis (DVT) diagnostic algorithm.Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation.
P50
Q24202077-B2AD1622-F211-4946-9D3E-6AA0087D7C48Q24563574-746331AC-FF46-4938-8035-BE5CC713EA6BQ26470376-7ED9D39B-B969-4B6D-B2D4-C4F740A689A7Q33371013-E4C8E1C2-6938-40F9-B9A0-BBEAA41A3328Q33395240-E02A333C-F25E-45A1-96FB-3E4AC8E5CA08Q33403703-17E883C8-9A1E-4028-AB56-C816D9845901Q33441370-858DA11A-8296-4B23-ACFA-8E1456F4EEDAQ33492384-FDFA5AEA-72BF-45DF-B0E3-AFB03306FE27Q33559159-6E5D1614-F758-4A5B-8628-88754A8F8C5DQ34313804-BE67CE15-0AAF-4B8C-9A28-6BD7DF30A070Q34401174-9AC96D61-A48E-4810-AA68-3546BD1A4D88Q34494896-3E8BE541-F475-4D98-A858-DD1190B7C181Q34816051-A932360C-A7C1-46E1-9882-3E180A168A8FQ35565498-CD0EB626-B4F8-4979-9453-55560D1BC2B6Q36306970-1F315FE5-6A16-4308-8285-65E13A297D98Q36366534-D7747F01-7852-40EF-8181-42B7BC928B3FQ36480548-9009D1DF-7BDD-4DAA-BADE-8BBD00C2092DQ37076516-0006D0F6-7EB0-4887-8481-9A9A7A6326E0Q37532738-96329F37-F9DD-45E2-9501-210569500E0CQ37552621-CC97F1C7-051A-4F26-8779-B3FBA0787B05Q37965902-2F47B33A-0337-4898-BA04-C24AFA399743Q38201452-AD412A08-115A-4D14-82AA-D92A66F84A64Q38230831-97B81F9F-A565-4BDE-9F0C-DB0AA9B7DD61Q38560286-FC4D7710-86BD-4C6D-9CE5-EE732D03D820Q38768065-D40E2BEC-CCF0-4010-81D9-806C2BC39576Q38867485-CC6223C6-8DC1-4FB6-98B7-B6112FD1CF6EQ42550007-8B0C7F0B-6B97-4875-A3CD-68F6A33012F3Q42623251-9EF5C630-60B1-4D83-A6D5-FAC75D4C82B1Q42786623-2B61B199-4CC1-4EEF-9775-9E738D492208Q43165420-BF3A3CC9-3A30-4C51-BBD0-058E8CDCAEBBQ43227487-513F728B-5715-4996-94C7-2222703B8AB1Q44089616-85CB14A6-42AD-4027-A912-D706186AB3F2Q44584056-23A9A7D5-F716-4D9F-89D0-354CCDB730F1Q44694348-949A30EA-128F-4C9A-938E-073776EE26D8Q45007433-239A474A-6FCC-459D-9AA4-E8E04680A0DAQ45857408-F4CAEE9E-3B7D-423F-88D8-B46C423334FDQ45859109-CB9E99A4-5446-4DC0-ABB1-27046B24A9B1Q45861536-81BE6CFB-AD15-4C91-8857-E96E34E95D73Q45862888-45018DD7-BD75-4C07-8D88-C01E76DEBF16Q45863186-BE4A54A6-BC7E-4452-8A9B-FA8EFB123552
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
David Keeling
@ast
David Keeling
@en
David Keeling
@es
David Keeling
@nl
David Keeling
@sl
type
label
David Keeling
@ast
David Keeling
@en
David Keeling
@es
David Keeling
@nl
David Keeling
@sl
prefLabel
David Keeling
@ast
David Keeling
@en
David Keeling
@es
David Keeling
@nl
David Keeling
@sl
P106
P21
P31
P3835
david-keeling
P496
0000-0001-6779-6566